Cargando…
Engineered Viruses as Vaccine Platforms
Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vacc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120934/ http://dx.doi.org/10.1007/978-94-007-4543-8_4 |
_version_ | 1783515086333149184 |
---|---|
author | Folgori, Antonella Capone, Stefania |
author_facet | Folgori, Antonella Capone, Stefania |
author_sort | Folgori, Antonella |
collection | PubMed |
description | Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes. |
format | Online Article Text |
id | pubmed-7120934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71209342020-04-06 Engineered Viruses as Vaccine Platforms Folgori, Antonella Capone, Stefania Innovation in Vaccinology Article Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes. 2012-03-29 /pmc/articles/PMC7120934/ http://dx.doi.org/10.1007/978-94-007-4543-8_4 Text en © Springer Science+Business Media Dordrecht 2012 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Folgori, Antonella Capone, Stefania Engineered Viruses as Vaccine Platforms |
title | Engineered Viruses as Vaccine Platforms |
title_full | Engineered Viruses as Vaccine Platforms |
title_fullStr | Engineered Viruses as Vaccine Platforms |
title_full_unstemmed | Engineered Viruses as Vaccine Platforms |
title_short | Engineered Viruses as Vaccine Platforms |
title_sort | engineered viruses as vaccine platforms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120934/ http://dx.doi.org/10.1007/978-94-007-4543-8_4 |
work_keys_str_mv | AT folgoriantonella engineeredvirusesasvaccineplatforms AT caponestefania engineeredvirusesasvaccineplatforms |